What are the indications, dosing regimens, and monitoring considerations for doxepin and doxazosin?

Doxepin and Doxazosin: Clinical Overview

Doxepin

Doxepin is a tricyclic antidepressant with multiple FDA-approved and off-label indications, primarily used in dermatology for pruritus, psychiatry for depression/anxiety, and sleep medicine for insomnia.

Indications

Primary approved uses:

• Insomnia (particularly sleep maintenance): Low-dose doxepin (1-6 mg) is highly effective for improving total sleep time and wake after sleep onset 1
• Neuropathic pain: As a first-line coanalgesic for cancer-related and non-cancer neuropathic pain 2, 3
• Major depressive disorder and anxiety: At higher doses (typically 75-300 mg/day) 4
• Pruritus: Most efficacious antipruritic available to dermatologists 5

Dosing Regimens

For insomnia 6, 1:

• Start: 3-6 mg once nightly
• Maximum: 6 mg/day
• Evidence shows low doses (3-6 mg) improve sleep without significant anticholinergic burden

For neuropathic pain 3:

• Start: 10-25 mg at bedtime
• Titrate: Increase by 25 mg every 3-7 days as tolerated
• Maximum: 150 mg/day (can continue cautiously if blood levels of active drug + metabolite <100 ng/mL)
• Duration of adequate trial: 6-8 weeks with at least 2 weeks at maximum tolerated dose

For depression/anxiety 4:

• Therapeutic range: 75-300 mg/day
• FDA maximum: 300 mg/day
• Liquid concentrate (10 mg/mL) available for dose flexibility

Critical Monitoring Considerations

Pharmacogenomic testing 7, 5:

• CYP2C19 poor metabolizers (PM) and ultrarapid metabolizers (UM): Consider alternatives (nortriptyline or desipramine) due to unpredictable metabolism
• CYP2D6 ultrarapid metabolizers: Consider 50% dose reduction or alternative agents
• Blood level monitoring is valuable when patients fail typical dermatologic doses (10-25 mg) - allows safe dose escalation rather than labeling as treatment failure 5

Cardiovascular monitoring 3:

• Obtain screening ECG in patients >40 years before initiating therapy
• Limit doses to <100 mg/day when possible in patients with ischemic cardiac disease or ventricular conduction abnormalities
• Cardiac toxicity is the primary concern with tricyclic antidepressants

Suicide risk monitoring 4:

• Black Box Warning: Increased suicidality risk in patients <24 years, especially during initial months and dose changes
• Monitor closely for clinical worsening, agitation, panic attacks, insomnia, irritability, hostility, akathisia
• Prescribe smallest quantity consistent with good management

Angle-closure glaucoma screening 4:

• Screen for anatomically narrow angles before initiating - pupillary dilation can trigger angle-closure attack

Key Adverse Effects

• Low doses (insomnia): Minimal anticholinergic effects, drowsiness, dizziness 1
• Higher doses: Sedation, dry mouth, urinary hesitancy, constipation, weight gain 3
• Avoid abrupt discontinuation - taper over 10-14 days to prevent withdrawal 8

---

Doxazosin

Doxazosin is an alpha-1 adrenergic blocker FDA-approved for benign prostatic hyperplasia (BPH) and hypertension, with emerging evidence for PTSD-related nightmares and substance use disorders.

Indications

FDA-approved:

• Benign prostatic hyperplasia: First-line alpha-blocker for lower urinary tract symptoms 9, 10
• Hypertension: Effective but not first-line; reserved for resistant hypertension or specific scenarios 11, 12

Off-label uses with evidence:

• Pheochromocytoma: Alpha-blockade before surgical resection 11
• PTSD nightmares: Emerging evidence as alternative to prazosin with once-daily dosing advantage 13
• Cocaine use disorder: Promising evidence for reducing sympathetic arousal 13

Dosing Regimens

For BPH 9, 10:

• Start: 1 mg once daily (morning or evening)
• Titrate: Double dose at 1-2 week intervals based on response
• Progression: 1 mg → 2 mg → 4 mg → 8 mg
• Maximum: 8 mg once daily
• Mean effective dose in studies: 4-6.4 mg/day 14

For hypertension 10:

• Start: 1 mg once daily
• Titrate: May double dose as needed
• Maximum: 16 mg once daily
• Critical: Monitor BP for at least 6 hours after initial dose and each dose increase

For pheochromocytoma 11:

• Preoperative preparation: 2-4 mg two to three times daily for 10-14 days
• Ensure adequate alpha-blockade before adding beta-blockers

For resistant hypertension 15, 16:

• Typically added as 4th-5th line agent
• Dose range: 2-16 mg/day
• Mean BP reduction: 11.7/6.9 mmHg when added to 2+ other agents

Critical Monitoring Considerations

First-dose hypotension 10:

• Most important safety concern: Monitor BP for minimum 6 hours after initial dose and each increase
• Start in morning or evening based on patient schedule
• If therapy interrupted for several days, restart at 1 mg (do not resume previous dose)

Orthostatic hypotension screening:

• Check standing and supine BP, especially in elderly and those with autonomic neuropathy 11
• Common adverse events: dizziness (most frequent), fatigue, headache, edema 14, 15
• Discontinuation rate for adverse events: 5-7.5% 14, 16

Routine BP monitoring:

• Essential in BPH patients even if normotensive at baseline 9
• Normotensive BPH patients experience modest BP decrease (~4/2 mmHg) that is usually not clinically significant 14

Metabolic monitoring 15:

• Favorable effects on lipid profiles (modest)
• Small rise in fasting glucose observed
• No excess heart failure risk when used as add-on therapy

Contraindications and Cautions

• Avoid in patients with severe hepatic impairment (reduce maximum to 2 mg) 10
• Use cautiously in elderly and debilitated patients (start 1 mg, slower titration)
• Do not combine with alpha-blockers + low-dose tadalafil for BPH - no additional benefit and higher side effects 9

Special Populations

BPH with acute urinary retention 9:

• Prescribe alpha-blocker before voiding trial
• Complete at least 3 days of therapy before trial without catheter
• Improves success rate of catheter removal

Combination therapy for BPH 9:

• Alpha-blocker + 5-ARI (finasteride/dutasteride): Proven to reduce clinical progression in large prostates
• Alpha-blocker + anticholinergic: Reasonable in storage-predominant symptoms with elevated post-void residual monitoring
• Alpha-blocker + beta-3 agonist: May improve symptoms similar to anticholinergics

---

Key Clinical Pearls

Doxepin:

• Secondary amine tricyclics (nortriptyline, desipramine) are better tolerated alternatives if doxepin causes excessive anticholinergic effects 2, 3
• For insomnia, low-dose doxepin (3-6 mg) avoids most tricyclic side effects while maintaining efficacy 1
• Blood level monitoring transforms management in treatment-resistant cases 5

Doxazosin:

• The 6-hour post-dose BP monitoring requirement is non-negotiable for safety 10
• Effective as 4th-5th line agent in resistant hypertension despite guideline de-emphasis 15, 16
• Once-daily dosing advantage over prazosin makes it attractive for PTSD nightmares 13
• Restart at 1 mg if interrupted - do not resume previous dose 10